Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4496-4500

  Fillion, Aurélie ^a,b   Aubry, Alexandra ^a,c,d   Brossier, Florence ^a,c,d   Chauffour, Aurélie ^a   Jarlier, Vincent ^a,c,d   Veziris, Nicolas ^a,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL DU BOCAGE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHIONAMIDE; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; DRUG EFFICACY; FEMALE; LUNG HOMOGENATE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; TUBERCULOSIS; WILD TYPE;

AMIKACIN; ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DNA GYRASE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ETHIONAMIDE; FEMALE; FLUOROQUINOLONES; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES; RECURRENCE; RODENT DISEASES; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 84882446570     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00506-13     Document Type: Article

References (43)

1. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. 2008. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 300:2153-2160.
2. Kliiman K, Altraja A. 2009. Predictors of poor treatment outcome in multi-and extensively drug-resistant pulmonary TB. Eur. Respir. J. 33: 1085-1094.
3. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 51:6-14.
4. World Health Organization. 2011. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015:WHOprogress report 2011. U.S. patent WHO/HTM/ TB/2011.3. World Health Organization, Geneva, Switzerland.
5. Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, Kim EK, Lee KM, Lee S-S, Park JS, Koh W-J, Lee C-H, Shim TS. 2010. Treatment outcomes and survival based on drug resistance patterns in multidrugresistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:113-119.
6. World Health Organization. 2001. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-Plus. World Health Organization, Geneva, Switzerland.
7. Aubry A, Pan X-S, Fisher LM, Jarlier V, Cambau E. 2004. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. 48:1281-1288.
8. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, III, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
9. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 67:1088-1093.
10. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. 2006. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112.
11. Cheng AFB, Yew WW, Chan EWC, Chin ML, Hui MMM, Chan RCY. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601.
12. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. doi:10 .1371/journal.pone.0039754.
13. Ginsburg AS, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442.
14. Poissy J, Aubry A, Fernandez C, Lott M-C, Chauffour A, Jarlier V, Farinotti R, Veziris N. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob. Agents Chemother. 54:4765-4771.
15. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 47:3117-3122.
16. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 67:819-831.
17. Veziris N, Truffot C, Mainardi J-L, Jarlier V. 2011. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob. Agents Chemother. 55:2597-2600.
18. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. 2011. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 6:e17556. doi:10.1371/journal.pone.0017556.
19. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. 2005. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 172:1457-1462.
20. Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857.
21. Guillemin I, Jarlier V, Cambau E. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088.
22. Brossier F, Veziris N, Jarlier V, Sougakoff W. 2009. Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int. J. Tuberc. Lung Dis. 13:260-265.
23. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J. Clin. Microbiol. 47: 1773-1780.
24. Cynamon MH, Zhang Y, Harpster T, Cheng S, DeStefano MS. 1999. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob. Agents Chemother. 43:2922-2924.
25. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
26. Cynamon MH, Sklaney M. 2003. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob. Agents Chemother. 47:2442-2444.
27. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. 2013. Contribution of moxifloxacin or levofloxacin in secondline regimens with or without continuation of pyrazinamide in murine tuberculosis. Am. J. Respir. Crit. Care Med. 188:97-102.
28. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. 2006. Combinations of R207910 with drugs used to treat multidrugresistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50:3543-3547.
29. Tahaoǧlu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Ozmen I, Kapakli N. 2001. The treatment of multidrug-resistant tuberculosis in Turkey. N. Engl. J. Med. 345:170-174.
30. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. 2009. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4:e6914. doi:10.1371/journal.pone.0006914.
31. Allou N, Cambau E, Massias L, Chau F, Fantin B. 2009. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob. Agents Chemother. 53:4292-4297.
32. Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H, Chavanet P. 2004. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J. Antimicrob. Chemother. 54:640-647.
33. Croisier D, Chavanet P, Lequeu C, Ahanou A, Nierlich A, Neuwirth C, Piroth L, Duong M, Buisson M, Portier H. 2002. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J. Antimicrob. Chemother. 50:349-360.
34. Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S, Segler SD, Megginson M, Luedeman LJ, Shiferaw B, Hanna SS, Joyce KW, Mintz ED, Angulo FJ. 2008. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet multicenter retrospective cohort study. Antimicrob. Agents Chemother. 52:1278-1284.
35. Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, Diep TS, Day NP, Solomon T, White NJ, Piddock LJ, Parry CM. 1997. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25:1404-1410.
36. Pitaksajjakul P, Wongwit W, Punprasit W, Eampokalap B, Peacock S, Ramasoota P. 2005. Mutations in the gyrA and gyrB genes of fluoroquinolone- resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36(Suppl 4):228-237.
37. Duong DA, Nguyen THD, Nguyen TNL, Dai VH, Dang TMH, Vo SK, Do DAT, Nguyen VVC, Nguyen HD, Dinh NS, Farrar J, Caws M. 2009. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53:4835-4839.
38. Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A. 2012. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob. Agents Chemother. 56:1990-1996.
39. Andries K, Gevers T, Lounis N. 2010. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother. 54:4540-4544.
40. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. 2009. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med. 180:553-557.
41. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
42. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
43. Van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. 2009. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 53: 849-862.